(72) concluded that IGF-1 concentration is a biomarker of OSAHS severity, and that using IGF-1 measurements in the personalized treatment of patients with OSAHS may be useful for grading disease severity and guiding specific interventions for OSAHS-related cardiometabolic risk. This evidence concerns the gene IGF1 and obstructive sleep apnea syndrome.